학술논문
Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
Document Type
Article
Author
Source
In: Current Oncology . (Current Oncology, July 2023, 30(7):6559-6574)
Subject
Language
English
ISSN
17187729